<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>For younger patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), an allogeneic transplant from a matched sibling may afford the best chance of cure </plain></SENT>
<SENT sid="1" pm="."><plain>In patients who are older or without a matched sibling donor, dose intensification can be achieved with an autologous bone marrow transplant (ABMT) </plain></SENT>
<SENT sid="2" pm="."><plain>We report here the results of a high-dose chemotherapy regime with nonpurged ABMT in 82 adult patients in first remission of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with a median follow-up of 31 months </plain></SENT>
<SENT sid="3" pm="."><plain>The median age was 40 years (range 16 to 57 years) </plain></SENT>
<SENT sid="4" pm="."><plain>The median interval between remission and ABMT was 5 months (range 1 to 12 months) </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-eight of these patients received a second course of the same high-dose chemotherapy and ABMT </plain></SENT>
<SENT sid="6" pm="."><plain>The procedure related mortality rate was 6% </plain></SENT>
<SENT sid="7" pm="."><plain>The projected <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e>) at 5 years is 48% for <z:hpo ids='HP_0000001'>all</z:hpo> 82 patients and 50% for the 76 patients with no known preceding <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>For those patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> who received a double ABMT the projected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> is 67% </plain></SENT>
<SENT sid="9" pm="."><plain>The interval between remission and ABMT did not predict for either relapse or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>ABMT using a multidrug chemotherapy protocol is less toxic than allogeneic BMT yet results in a similar <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> </plain></SENT>
</text></document>